Literature DB >> 8143834

Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects.

L Borgström1, E Bondesson, F Morén, E Trofast, S P Newman.   

Abstract

We wanted to evaluate whether lung deposition of budesonide and terbutaline sulphate differs, and to determine lung deposition of budesonide inhaled at different peak inspiratory flows, through Turbuhaler. Lung deposition of budesonide, a lipophilic substance, and of terbutaline sulphate, a hydrophilic substance, was therefore compared, after administration via an inspiratory flow-driven, multi-dose, powder inhaler (Turbuhaler, Astra Draco AB) to 10 healthy volunteers. The radionuclide 99mTc was used to label drug particles, and radioactivity, indicating drug deposition, was measured using a gamma camera. Budesonide was inhaled at a normal flow of 58 l.min-1 and at a slow flow of 36 l-min-1. At the faster flow, a mean +/- SD 27.7 +/- 9.5% of the metered dose was deposited in the lung and at the slower flow 14.8 +/- 3.3% was deposited (p < 0.001). Mean lung deposition of terbutaline sulphate inhaled at 57 l.min-1 was 27.0 +/- 7.7%. We conclude that inspiratory flow has an important effect on lung deposition, but water solubility appears to have no effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8143834     DOI: 10.1183/09031936.94.07010069

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  43 in total

1.  Optical feedback training of inhalation with Autohaler and Turbuhaler in COPD patients.

Authors:  J Steier; T Trammer; R M Cloes; W Petro
Journal:  Lung       Date:  2003       Impact factor: 2.584

Review 2.  Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 3.  Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases.

Authors:  Istvan Szelenyi
Journal:  Inflamm Res       Date:  2011-11-05       Impact factor: 4.575

Review 4.  The economic aspects of drug delivery in asthma.

Authors:  R J Massie; C M Mellis
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

Review 5.  Deposition and effects of inhaled corticosteroids.

Authors:  Stephen P Newman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Optimizing inhaled drug delivery in patients with asthma.

Authors:  C Jackson; B Lipworth
Journal:  Br J Gen Pract       Date:  1995-12       Impact factor: 5.386

7.  An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers.

Authors:  A Lönnebo; A Grahnén; B Jansson; R M Brundin; A Ling-Andersson; S A Eckernäs
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

8.  Particle size selection device for use with the Turbohaler.

Authors:  M L Everard; S G Devadason; P N Le Souef
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

Review 9.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

10.  An alternative aerosol delivery system for amiloride.

Authors:  M L Everard; S G Devadason; V B Sunderland; P N Le Souef
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.